Tilray Brands, Inc. (TLRY)
- Previous Close
1.6400 - Open
1.6800 - Bid 1.7400 x 400
- Ask 1.7500 x 500
- Day's Range
1.6700 - 1.8200 - 52 Week Range
1.4500 - 2.9700 - Volume
56,507,398 - Avg. Volume
22,381,676 - Market Cap (intraday)
1.576B - Beta (5Y Monthly) 2.19
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2700 - Earnings Date Jan 7, 2025 - Jan 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.24
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Beverage Alcohol, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, Navcora, Charlotte's Web, Montauk Brewing, Shock Top, 10 Barrell, Breckenridge Brewery, SweetWater Brewing, Breckenridge Distillery, Blue Point Brewing, Broken Coast, Redecan, XMG, Manitoba Harvest, CC Pharma, Good Supply, Solei, Mollo, Chowie Wowie, Original Stash, Canaca, RIFF, Bake Sale, The Batch, HEXO, Alpine Beer Company, Green Flash, Hiball Energy, Redhook Brewery, Square Mile Cider, Widmer Brothers Brewing, Runner's High Brewing Company, Happy Flower, and Fresh Hemp Foods brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. and changed its name to Tilray Brands, Inc. in January 2022. Tilray Brands, Inc. is headquartered in Leamington, Canada.
www.tilray.com2,650
Full Time Employees
May 31
Fiscal Year Ends
Sector
Recent News: TLRY
View MoreRelated Videos: TLRY
Performance Overview: TLRY
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLRY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLRY
View MoreValuation Measures
Market Cap
1.48B
Enterprise Value
1.59B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.59
Price/Book (mrq)
0.43
Enterprise Value/Revenue
1.96
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.18%
Return on Assets (ttm)
-1.40%
Return on Equity (ttm)
-5.84%
Revenue (ttm)
812.04M
Net Income Avi to Common (ttm)
-212.62M
Diluted EPS (ttm)
-0.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
280.06M
Total Debt/Equity (mrq)
11.15%
Levered Free Cash Flow (ttm)
-35.79M
Research Analysis: TLRY
View MoreCompany Insights: TLRY
TLRY does not have Company Insights
Research Reports: TLRY
View MoreTilray Earnings: Alcohol Continues to Grow in Importance but Offers Limited Synergy to Cannabis
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
RatingPrice TargetTilray's Mix of Alcohol and Cannabis Businesses Fails to Generate Synergies or a Moat
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
RatingPrice TargetTilray Earnings: Decent End to Fiscal 2024, but We See Limited Risk-Adjusted Upside
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
RatingPrice TargetTilray's Mixed Portfolio Unlikely to Yield Synergies as Canadian Market Remains a Major Challenge
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.
RatingPrice Target